이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

외상성 늑골 골절에서 케타민 대 리도카인

2026년 11월 2일 업데이트: Brittany Hoyte

외상성 늑골 골절 환자의 복합 통증 관리를 위한 케타민 대 리도카인 주입의 전향적, 무작위, 단일 맹검 시험

Rib fractures continue to be a common occurrence in trauma patients of all ages. Traumatic rib fractures can cause severe pain in patients and lead to shallow breathing and further complications such as the need for mechanical ventilation, hospital or ventilator associated pneumonia, atelectasis, and acute respiratory distress syndrome. Effective multimodal pain management is needed to optimize a patient's respiratory status and can also play a role in early mobility, less pulmonary complications, shorter ICU and hospital length of stay, and decreased mortality. Current multimodal pain management options include opioids, muscle relaxants, gabapentin, acetaminophen, nonsteroidal anti-inflammatory drugs, and various regional/neuraxial anesthesia techniques. Both ketamine and lidocaine infusions for pain control have also been shown in studies to be safe and effective, with the benefit of minimizing the use of opioids. However, there have been very few studies that have used ketamine or lidocaine infusions for pain control specifically in patients with traumatic rib fractures. Therefore, the purpose of this study is to evaluate ketamine versus lidocaine infusions as an adjunctive therapy to reduce opioid consumption in the first 72 hours in patients with multiple traumatic rib fractures.

연구 개요

상세 설명

Effective pain control plays a key role is optimizing a patient's respiratory status after suffering multiple rib fractures. Using multimodal pain management techniques and optimizing a patient's pain control regimen helps to minimize the complications associated with rib fractures, such as pneumonia and the need for mechanical ventilation. The benefit of using opioid-sparing options such as ketamine or lidocaine infusions would be to avoid the side effects associated with opioids, which include delirium, constipation, and depressed respiratory drive.

Ketamine and lidocaine infusions are both medications that have been used in numerous studies to effectively treat post-operative pain. Low dose ketamine infusions have also recently been shown to be a safe and effective adjunct option to help reduce pain scores and decrease opioid use in patients with traumatic rib fractures. Currently there is no published studies to assess lidocaine's effectiveness to reduce pain scores and opioid use in traumatic rib fracture patients. There is also only one study to date that has directly compared ketamine to lidocaine infusions for pain control. This study occurred in 60 patients undergoing elective nephrectomy and evaluated three 24-hour infusion groups: ketamine, lidocaine, or placebo. The primary outcome showed that both ketamine and lidocaine infusions significantly reduced 24-hour OME compared to placebo (33% ketamine, 42% lidocaine) and decreased overall pain scores.

This trial is a single center, prospective, randomized trial of adult patients with ≥ 3 traumatic rib fractures admitted to a Level 1 trauma center at Spectrum Health Butterworth Hospital. As part of the current rib fracture protocol all patients will receive the standard multimodal pain regimen at the investigator's institution, including acetaminophen, NSAIDS, muscle relaxants and gabapentin. Currently ketamine infusions and regional/neuraxial anesthesia techniques are added if the standard multimodal pain regimen is insufficient. Lidocaine infusions have also been used at the institution for post-surgical pain control to minimize opioid use. The objective of the study will be to compare ketamine versus lidocaine infusions on the effectiveness to optimize pain control as well as minimize the use of opioids in patients with traumatic rib fractures.

If consent is obtained the patient will be randomized 1:1 to receive either a ketamine or lidocaine infusion for pain control, along with standard of care, using a pre-designed randomization schedule. Patients must be enrolled within 16 hours of hospital admission and are expected to remain on the infusion for a minimum of 24 hours. The duration, titration, and stopping of study drug will be dependent on the progress of the patient's overall pain status and provider decision, with data being included for the study medication for up to 72 hours. If patients require surgery at any time the study medication will not be held unless signs of adverse events occur. Patients who are unable to remain on the study infusion or have a regional/neuraxial anesthetic placed before the 24-hour mark (decided based on the Trauma and Surgical Intensive Care Unit services) will be considered a screen fail and no data will be contributed to the study, however, the screen fail will be documented. If a patient is unable to remain on infusion or has a regional/neuraxial anesthetic placed ≥ 24 hours, their data will be included up until that point and analyzed. Adverse event and serious adverse events will be monitored throughout the entire study period, with continuous cardiac telemetry being required in both study groups and daily lidocaine levels drawn in the lidocaine group.

연구 유형

중재적

등록 (실제)

61

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Michigan
      • Grand Rapids, Michigan, 미국, 49503
        • Corewell Health West

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Adults ≥ 18 years old
  2. ≥ 3 traumatic blunt rib fractures
  3. Enrollment within 16 hours of being admitted to the hospital
  4. Patients whom in the investigator's clinical judgement, would require escalated pain control regiments in the future and would potentially benefit from participation in this study in terms of pain control.

Exclusion Criteria:

  1. Patients receiving any regional/neuraxial anesthetic techniques or ketamine infusion before randomization

  2. Adults with diminished decision-making capacity

  3. Adults of limited English proficiency/non-English speakers

  4. Prisoners

  5. Pregnant or breastfeeding women

  6. Patient admission weight greater than 120 kg

  7. Patients with any of the following medical history:

    1. Active delirium (as defined by Confusion Assessment Method)
    2. Dementia
    3. Psychosis
    4. Glaucoma
    5. Heart block (except with patients with a functioning artificial pacemaker)
    6. Congestive heart failure (ejection fraction <20% recorded in last year)
    7. Adams-Stokes syndrome
    8. Wolff-Parkinson-White Syndrome
  8. Patient is unable to communicate with staff for pain assessments at time of enrollment

  9. Most recent documented Glasgow Coma Score <15 at the time of study enrollment

  10. Severe bradycardia (heart rate <50 bpm based on last vital sign recorded at time of study enrollment)

  11. Sustained hypertension (systolic blood pressure >180 mm Hg or diastolic blood pressure >100 mm Hg for at least 3 sets of vital signs in a row prior to study enrollment)

  12. Any seizure suspected or identified during hospital admission

  13. Patient with active acute coronary syndrome obtained from admission problem list

  14. Patients with known hepatic disease or acute liver failure

    a. Acute liver failure on admission defined as either: i. International normalized ratio > 1.5, without being on home anticoagulation ii. Aspartate aminotransferase or Alanine aminotransferase greater than 120 IU/L (3 times upper limit of normal) b. Known hepatic disease defined as past medical history of Child Turcotte Pugh (Child's) score C

  15. Patients with a history of end-stage renal disease or admission creatinine clearance (CrCl) ≤30 ml/min

    a. CrCl will be based on Cockcroft-Gault equation from admission labs

  16. Use of antiarrhythmic medication therapy prior or during admission

    a. Amiodarone, sotalol, dofetilide, dronedarone, mexilitine

  17. Patients with a known allergy/sensitivity to lidocaine or ketamine, amide anesthetics, or components of the solution

  18. Patients who, in the investigator's opinion, should not be included in this study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Ketamine

Infusion initiation: 0.1 mg/kg/hr Max: 0.3 mg/kg/hr Recommended titration: 0.1 mg/kg/hr* as needed every 4 hours based on pain scores ≥5 and physician order

Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission.

Will receive titratable infusion.

다른 이름들:
  • 케탈라르
활성 비교기: Lidocaine

Infusion initiation: 1 mg/kg/hr Max: 2 mg/kg/hr Recommended titration:0.25 mg/kg/hr* as needed every 4 hours based on pain scores ≥5 and physician order

Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission.

Will receive titratable infusion, will have daily lidocaine level labs drawn daily.

다른 이름들:
  • 실로카인

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Oral Morphine Equivalent - Opioid Usage
기간: 0-24 hours post infusion

Oral morphine equivalence is a way to track the amount of opioids used by standardizing all opioid utilizations and converting them to daily morphine equivalence in mg.

0-24 hours post infusion

2차 결과 측정

결과 측정
측정값 설명
기간
Visual Analogue Numeric Pain Score
기간: 0-24; 24-48; 48-72 hours post infusion

Visual Analogue Numeric Pain Score are recorded as a scale of 1-10, with 0 being no pain and 10 as worst imaginable pain. Patient will be asked their pain score every 6 hours.

0-24; 24-48; 48-72 hours post infusion
Oral Morphine Equivalent - Opioid Usage
기간: 24-48; 48-72 hours post infusion

Oral morphine equivalence is a way to track the amount of opioids used by standardizing all opioid utilizations and converting them to daily morphine equivalence in mg.

24-48; 48-72 hours post infusion
Respiratory Failure
기간: 0-30 days post-infusion

Respiratory failure was defined by need for mechanical intubation

0-30 days post-infusion
Use of Regional/Neuraxial anesthesia
기간: 0-30 days post infusion

Measure of regional/neuraxial anesthesia placement rates. Patient would need to be taken off study medication if decision made to place regional/neuraxial anesthetic.

0-30 days post infusion
Hospital Length of Stay
기간: Will capture retrospectively after patient's medical discharge

Total hospital length of stay up to 365 days

Will capture retrospectively after patient's medical discharge
Intensive Care Unit Length of stay
기간: Will capture retrospectively after patient's medical discharge

Total intensive care unit length of stay up to 365 days

Will capture retrospectively after patient's medical discharge
Incentive Spirometry
기간: 0-24; 24-48; 48-72 hours post infusion

Measure of percent improvement in incentive spirometry level from baseline (before infusion). Incentive spirometry levels range from 0-4,000 mL.

0-24; 24-48; 48-72 hours post infusion
Adverse events
기간: 0-72 hours post infusion

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

0-72 hours post infusion
In-Hospital mortality
기간: Will capture retrospectively after patient's medical discharge

Patient's death will be recorded if it occurs before discharge

Will capture retrospectively after patient's medical discharge

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 4월 1일

기본 완료 (실제)

2024년 10월 10일

연구 완료 (실제)

2026년 7월 12일

연구 등록 날짜

최초 제출

2021년 2월 22일

QC 기준을 충족하는 최초 제출

2021년 3월 1일

처음 게시됨 (실제)

2021년 3월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 4일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다